コンテンツへスキップ
Merck
  • Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.

Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2015-03-23)
Malte Kriegs, Kristin Gurtner, Yildiz Can, Ingo Brammer, Thorsten Rieckmann, Reinhard Oertel, Marek Wysocki, Franziska Dorniok, Andreas Gal, Tobias J Grob, Simon Laban, Ulla Kasten-Pisula, Cordula Petersen, Michael Baumann, Mechthild Krause, Ekkehard Dikomey
要旨

How EGF receptor (EGFR) inhibition induces cellular radiosensitization and with that increase in tumor control is still a matter of discussion. Since EGFR predominantly regulates cell cycle and proliferation, we studied whether a G1-arrest caused by EGFR inhibition may contribute to these effects. We analyzed human non-small cell lung cancer (NSCLC) cell lines either wild type (wt) or mutated in p53 (A549, H460, vs. H1299, H3122) and HCT116 cells (p21 wt and negative). EGFR was inhibited by BIBX1382BS, erlotinib or cetuximab; p21 was knocked down by siRNA. Functional endpoints analyzed were cell signaling, proliferation, G1-arrest, cell survival as well as tumor control using an A549 tumor model. When combined with IR, EGFR inhibition enhances the radiation-induced permanent G1 arrest, though solely in cells with intact p53/p21 signaling. This increase in G1-arrest was always associated with enhanced cellular radiosensitivity. Strikingly, this effect was abrogated when cells were re-stimulated, suggesting the initiation of dormancy. In line with this, only a small non-significant increase in tumor control was observed for A549 tumors treated with fractionated RT and EGFR inhibition. For NSCLC cells increase in radiosensitivity by EGFR inhibition results from enhanced G1-arrest. However, this effect does not lead to improved tumor control because cells can be released from this arrest by re-stimulation.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジメチルスルホキシド, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, for molecular biology
Sigma-Aldrich
ジメチルスルホキシド, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
ヨウ化プロピジウム, ≥94.0% (HPLC)
Sigma-Aldrich
ジメチルスルホキシド, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
ジメチルスルホキシド, PCR Reagent
Sigma-Aldrich
ジメチルスルホキシド, anhydrous, ≥99.9%
Sigma-Aldrich
ヨウ化プロピジウム 溶液
Sigma-Aldrich
ジメチルスルホキシド, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5%
Sigma-Aldrich
8-Octanoyloxypyrene-1,3,6-trisulfonic acid trisodium salt, suitable for fluorescence, ≥90% (HPCE)
Sigma-Aldrich
ジメチルスルホキシド, JIS special grade, ≥99.0%
Sigma-Aldrich
ジメチルスルホキシド, Vetec, reagent grade, 99%
Sigma-Aldrich
ジメチルスルホキシド, suitable for HPLC
Sigma-Aldrich
MISSION® esiRNA, targeting human KRAS
Sigma-Aldrich
ジメチルスルホキシド, SAJ first grade, ≥99.0%
Sigma-Aldrich
ジメチルスルホキシド, ≥99.0%, suitable for absorption spectrum analysis
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Nsg1
Sigma-Aldrich
MISSION® esiRNA, targeting human TPT1